Active substance
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Baqsimi | 3 mg | Nasal spray · Nasal use | 2 Nasal Applicator | SAR 139.50 | NCE · Prescription | Eli Lilly and Company | Valid |
| GLUCAGEN HYPOKIT | 1 mg | Powder and solvent for solution for injection · Subcutaneous use | 1 Vial | SAR 86.55 | Generic · Prescription | NOVO NORDISK | Valid |
| GLUCAGEN powder and solvent for solution for injection | 1 mg | Powder and solvent for solution for injection · Subcutaneous use | 1 Vial | SAR 52.55 | Generic · Prescription | NOVO NORDISK | Withdrawn by MAH · Not Marketed |
| GLUCAGON 1 MG VIAL+SOLVENT 1ML | 1 mg | Powder for injection · Subcutaneous use | 1 Vial | SAR 37.30 | NCE · Prescription | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
| GLUCAGON 10MG VIAL+SOLVENT | 10 mg | Powder for injection · Subcutaneous use | 1 Vial | SAR 311.05 | NCE · Prescription | Eli Lilly and Company | Withdrawn by MAH · Not Marketed |
ANAPHYLACTIC SHOCK; HYPOGLYCEMIA
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| GLUCAGON | EQ 1MG BASE/VIAL | powder · intramuscular, intravenous | FRESENIUS KABI USA | Prescription | 8 May 2015 |
| GLUCAGON | EQ 1MG BASE/VIAL | powder · intramuscular, intravenous, subcutaneous | FRESENIUS KABI USA | Prescription | 8 May 2015 |
| BAQSIMI | 3MG | powder · nasal | AMPHASTAR PHARMS INC | Prescription | 24 Jul 2019 |
| GVOKE PFS | 1MG/0.2ML (1MG/0.2ML) | solution · subcutaneous | XERIS | Prescription | 10 Sep 2019 |
| GVOKE HYPOPEN | 0.5MG/0.1ML (0.5MG/0.1ML); 1MG/0.2ML (1MG/0.2ML) | solution · subcutaneous | XERIS | Prescription | 10 Sep 2019 |
| GVOKE KIT | 1MG/0.2ML (1MG/0.2ML) | solution · subcutaneous | XERIS | Prescription | 10 Sep 2019 |
| GLUCAGON | 1MG/VIAL | injectable · injection | AMPHASTAR PHARMS INC | Prescription | 28 Dec 2020 |
| GLUCAGON | 1MG/VIAL | injectable · injection | MYLAN LABS LTD | Prescription | 12 Dec 2024 |
| GLUCAGON | 1MG/VIAL | injectable · injection | LUPIN | Prescription | 22 Jul 2025 |
| GLUCAGON | 1MG/VIAL | injectable · injection | CIPLA | Prescription | 15 Sep 2025 |
| GLUCAGON | EQ 1MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; EQ 10MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | LILLY | Discontinued | 14 Nov 1960 |
| GLUCAGEN | EQ 1MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | powder · intramuscular, intravenous | NOVO NORDISK | Discontinued | 22 Jun 1998 |
| GLUCAGEN | EQ 1MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | powder · intramuscular, intravenous, subcutaneous | NOVO NORDISK | Discontinued | 22 Jun 1998 |
| GLUCAGON | 1MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | LILLY | Discontinued | 11 Sep 1998 |
| GVOKE PFS | 0.5MG/0.1ML (0.5MG/0.1ML) | solution · subcutaneous | XERIS | Discontinued | 10 Sep 2019 |
| GVOKE VIALDX | 1MG/0.2ML (1MG/0.2ML) | solution · intravenous | XERIS | Discontinued | 10 Sep 2019 |
| GLUCAGON | EQ 1MG BASE/VIAL | injectable · injection | QUAD PHARMS | Discontinued | |
| GLUCAGON | EQ 10MG BASE/VIAL | injectable · injection | QUAD PHARMS | Discontinued |
Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.
Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| BAQSIMI | 02492415 | 3 MG / CONTAINER | POWDER · NASAL | AMPHASTAR PHARMACEUTICALS, INC. |
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | BAQSIMI 3 MG SPRAY | $292.98014 | per EA | 23 Sep 2026 |
| US NADAC | BAQSIMI 3 MG SPRAY ONE PACK | $292.98014 | per EA | 23 Sep 2026 |
| US NADAC | BAQSIMI 3 MG SPRAY TWO PACK | $293.03517 | per EA | 23 Sep 2026 |
| US NADAC | GLUCAGON 1 MG EMERGENCY KIT | $154.20337 | per EA | 23 Sep 2026 |
| US NADAC | GLUCAGON 1 MG EMERGENCY KIT | $240.40425 | per EA | 23 Sep 2026 |
| US NADAC | GLUCAGON 1 MG VIAL | $154.20337 | per EA | 23 Sep 2026 |
| US NADAC | GLUCAGON 1 MG VIAL | $240.40425 | per EA | 23 Sep 2026 |
| US NADAC | GVOKE HYPOPEN 1-PK 1 MG/0.2 ML | $1603.18226 | per ML | 23 Sep 2026 |
| US NADAC | GVOKE HYPOPEN 2-PK 1 MG/0.2 ML | $1596.19346 | per ML | 23 Sep 2026 |
| US NADAC | GVOKE HYPOPEN 2PK 0.5 MG/0.1 ML | $3202.32985 | per ML | 23 Sep 2026 |
| US NADAC | GVOKE PFS 1-PK 1 MG/0.2 ML SYR | $1600.95652 | per ML | 23 Sep 2026 |
| US NADAC | GVOKE PFS 2-PK 1 MG/0.2 ML SYR | $1604.33929 | per ML | 23 Sep 2026 |
| NHS Drug Tariff | Glucagon 1mg powder and solvent for solution for injection vials | £11.52 | 1 vial | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.